Agenus Inc.
NASDAQ:AGENBiotechnology
-$0.01 today
- Market cap
- $289.58M
- Beta
- 1.54
- P/E (TTM)
- 1.7
- EPS (TTM)
- $1.70
Volume 0.88M
Average 0.82M
AGEN Common Stock Issued
Cash raised by issuing new shares.
Agenus Inc.NASDAQ: AGEN
Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026
Common stock issued grows, but more slowly than its trailing trend
Q1 FY2026 common stock issued of $7.47M rose 17.8% year over year, behind the +33.3% change in trailing-twelve-month common stock issued. Sequentially, it fell 13.7% from the prior quarter. Over 3 fiscal years it compounded at -28.5% a year.
Context
- Common stock issued amounted to 31.8% of revenue in FY2025, down 5.7 pp from a year earlier.
- Common stock issued increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +17.8% toward the trailing-twelve-month pace of +33.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 36.31M USD
- Year-over-year change
- -6.5%
- 4-year CAGR
- -36.3%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 36.31M | -6.5% |
| FY2024 | 2024-12-31 | 38.82M | -70.8% |
| FY2023 | 2023-12-31 | 133.16M | +34.2% |
| FY2022 | 2022-12-31 | 99.21M | -55.0% |
| FY2021 | 2021-12-31 | 220.65M | — |
Common Stock Issued vs competitors
How AGEN compares with its peers on the latest reported figures
- AGEN's LTM Mar 2026 common stock issued of $37.31M is the 3rd largest of the 10 companies compared; the peer median is $449K.
- Its year-over-year change of +33.3% is the 4th highest of 7, against a peer median of +55.4%.
- Common stock issued amounts to 30.1% of revenue for AGEN, versus a peer median of 3.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
IRDOpus Genetics, Inc. | LTM Mar 2026 | $56.66M | +577.7% | +123.1% | 472.9% |
| LTM Mar 2026 | $53.14M | +10.8% | -13.8% | — | |
| LTM Mar 2026 | $37.31M | +33.3% | -28.5% | 30.1% | |
| LTM Mar 2026 | $22.86M | — | +125.9% | — | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | $5.92M | — | — | — |
| LTM Mar 2026 | $4.14M | -1527.6% | — | — | |
| LTM Mar 2026 | $449K | — | — | 3.0% | |
| LTM Mar 2026 | $147K | +210.5% | -78.3% | — | |
| LTM Mar 2026 | $146K | -96.1% | -86.2% | — | |
| LTM Mar 2026 | $0 | +100.0% | — | 0.0% | |
| Peer median (excluding AGEN) | $449K | +55.4% | -13.8% | 3.0% | |
Competitors are the stored peer set for AGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (28.72M) | (230.66M) | (257.44M) | (232.27M) | (232.27M) |
| Depreciation & Amortization | 6.79M | 6.95M | 13.59M | 13.34M | 13.34M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 19.58M | 18.34M | 22.87M | 17.39M | 17.39M |
| Change in Working Capital | (9.74M) | 24.08M | 10.76M | 32.6M | 27.33M |
| Accounts Receivables | (394K) | 122K | (23.46M) | 25.34M | (1.73M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 10.82M | 6.49M | 21.37M | 2.01M | 23.5M |
| Other Working Capital | (20.17M) | 17.47M | 12.85M | 5.25M | 5.56M |
| Other Non-Cash Items | 22.25M | 5.92M | (13.98M) | 10.62M | 15.89M |
| Operating Cash Flow | 10.15M | (175.37M) | (224.2M) | (158.32M) | (158.32M) |
| Capital Expenditures | (33.81M) | (53.06M) | (9.95M) | (576K) | (576K) |
| Acquisitions (Net) | 0 | (2.92M) | 0 | 0 | 0 |
| Purchases of Investments | (14.99M) | (24.63M) | (20.04M) | 0 | 0 |
| Sales of Investments | 0 | 25M | 30.03M | 579K | 579K |
| Other Investing Activities | 5.66M | 22M | 3.36M | 24K | 24K |
| Investing Cash Flow | (43.15M) | (33.61M) | 3.4M | 27K | 27K |
| Debt Repayment | (1.32M) | (490K) | (8.93M) | 9.52M | 2.35M |
| Common Stock Issued | 220.65M | 99.21M | 133.16M | 38.82M | 36.31M |
| Common Stock Repurchased | (1.65M) | (3.79M) | (5.17M) | 0 | (87K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 7.59M | 898K | 807K | 74.5M | 84.27M |
| Financing Cash Flow | 225.26M | 95.83M | 119.87M | 122.84M | 122.84M |
| Effect of Forex Changes | (164K) | (104K) | (628K) | (260K) | (260K) |
| Net Change in Cash | 192.1M | (113.26M) | (101.56M) | (35.71M) | (35.71M) |
| Free Cash Flow | (23.67M) | (228.44M) | (234.16M) | (158.89M) | (158.89M) |
Agenus Inc.
NASDAQ:AGEN
Intrinsic Alpha fair value
Locked
Current Price
$6.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.